In this study, a series of derivatives of the amphipathic proline-rich sweet arrow peptide (SAP) were covalently linked to antisense oligonucleotides designed to inhibit Renilla luciferase gene. Oligonucleotide-peptide conjugates carrying lysine (Lys) and ornithine (Orn) residues were prepared using the stepwise approach by assembling first the peptide sequence followed by the assembly of the DNA molecule. The resulting Lys, Orn-conjugates were transformed to the corresponding arginine and homoarginine oligonucleotide-peptide conjugates by reaction with O-methylisourea. The introduction of the SAP at 3 -termini of a phosphorothioate oligonucleotide did not affect the ability to inhibit gene expression when transfected with lipofectamine. However, these conjugates were not able to enter cells without transfecting agent. Further studies using SAP as a transfection agent showed promising results for the conjugates carrying the Orn-SAP. All conjugates showed high duplex stabilities.
Introduction
Cell-penetrating peptides (CPPs) are considered to be promising delivery agents because they efficiently translocate across the plasma membrane being able to enter in the cells [1, 2] . These CPPs contain domains of less than 20 amino acids and are highly rich in basic residues. This process of translocation across the cell membrane was demonstrated for the first time when the 86-mer transactivating transcriptional activator, Tat protein, was internalized by cells [3] [4] [5] . Since then, researchers have been able to synthesize different and novel peptides or CPPs demonstrating this property of translocation; for instance, transportan [6] , synthetic polyarginines [7] , or TAT peptide [8] . To date, many modifications have been made in order to synthesize and optimize new CPPs as cellular delivery agents and introduce a variety of intracellular cargoes that have been transported by CPPs like liposomes [9] , polymers [10] , DNA [11] , or nanoparticles [12] [13] [14] .
Recently, Giralt and coworkers described a new family of amphipathic peptides showing moderate ability to cross the cell membrane in addition to the absence of a cytotoxic effect at high concentrations [12] [13] [14] [15] [16] [17] . This proline-rich peptide, called sweet arrow peptide (SAP) whose sequence is (ValXLeuProProPro) 3 (where X = His, Arg, or lysine (Lys) (K), respectively) is made up of 50% proline residues, is water soluble and contains three positively charged X residues favoring interaction with phospholipids anionic polar heads. After various cellular uptake experiments, it was found that two different SAP families (with X = Arg and Lys) could translocate human cell membranes. The positively charged and the amphipathic characteristics of SAP may be of interest for the delivery of negatively charged oligonucleotides in gene silencing experiments.
Oligonucleotides (ODNs) are important biomolecules involved in gene therapy [18, 19] . However, the activity of these compounds in vivo are compromised due to several factors like low stability against exonucleases, endonucleases present in serum [20] . Furthermore, delivery into cells is one of the bottlenecks encountered during the use of oligonucleotides in gene therapy. This is primarily due the fact that these compounds are large and negatively charged.
As a part of our ongoing interest in the development of chemically modified DNA [21] and siRNAs [22] [23] [24] to inhibit gene expression, we became interested on the use of CPP for improving cellular uptake of oligonucleotides conjugates. Some authors have already described the attachment of use of CCP for delivery of oligonucleotides [25] . Although the most common method for the use of CPP for transfection of oligonucleotides is by using complexes (polyplexes and lipoplexes) thereby taking advantage of the electrostatic interaction of charged oligonucleotides [25] , their stabilities could be compromised. In order to obtain more stable complexes and enhance resistance to the nuclease degradation of oligonucleotides, the use of a covalent linkage between CPPs and oligonucleotides has become an interesting alternative in overcoming the use of non-covalent methods which also has obtained promising biological results [26] . However, from a synthetic point of view, combining oligonucleotide chemistry with peptide chemistry covalently proves to be challenging. Surprisingly, the use of CPP-based delivery of antisense oligonucleotides has few references in literature [26] [27] [28] . Related to this field, promising results in nuclear delivery efficiencies were achieved for phosphorodiamidate morpholino oligomers (PMOs) that were conjugated to different CPPs such as Tat48-60 (Tat), oligoarginine (R 9 F 2 ), and the 6-aminohexanoic-spaced oligoarginine ((R-Ahx-R) 4 ), obtaining better transfection efficiencies for the last conjugate [28] .
In this study, we looked into the possibility of obtaining new CPP-oligonucleotide conjugates combining the proline-rich SAP with antisense oligonucleotides. Recently, our research group has successfully used this strategy with the synthesis of several CPPs linked to oligonucleotides through the stepwise approach [21] . In this study, we will describe on the conjugation of amphipathic proline-rich SAP [(ValXLeuProProPro) 3 , where X = Lys, Ornithine (Orn), Homoarginine (HArg), and Arginine (Arg), respectively] with DNA sequences using this covalent strategy where spacers of different lengths make up the formation of a covalent conjugate between the cargo and the 3 -termini of the oligonucleotides. This strategy was used to obtain an oligonucleotide phosphorothioate designed to inhibit the Renilla luciferase gene [21, 29] carrying the aformentioned SAP and the ability of these conjugates to inhibit gene expression was also evaluated in cells. The use of proline-rich peptides as non-viral vectors in cell transfection of plasmid DNA on solid lipid nanoparticles has been recently reported [30] ; however, to the best of our knowledge, it would be the first time that SAP in combination of antisense oligonucleotides in both covalent and electrostatic approaches is described for inhibition of gene expression.
Experimental section

Materials and methods
Protected amino acids were obtained from Novabiochem, Merck Chemicals (UK), and Bachem Gmbh (Germany). Poly (ethyleneglycol)-polystyrene resin (PEG-PS) was purchased from PerSeptive Biosystems, Inc. (USA). Coupling reagents: Benzotriazol-1-yloxytris(pyrrolidino)phosphonium hexafluorophosphate (PyBOP) was purchased from Sigma-Aldrich (USA) and 1-hydroxybenzotriazole (HOBt) was purchased from Albatros Chem Inc., Montreal, Canada. Solvents: Solvents for peptide synthesis and RP-HPLC equipment were obtained from Carlo Erba (Spain). Solvents for oligonucleotide synthesis were purchased from Applied Biosystems (USA). Trifluoroacetic acid (TFA), dimethylformamide (DMF), piperidine, and N ,N -diisopropylethylamine (DIEA) were purchased from Sigma-Aldrich (USA); dichloromethane (DCM) was purchased from Panreac (Spain). All commercial reagents and solvents were used as received. Semi-preparative RP-HPLC was performed on a Waters (Milford, MA) chromatography system using Symmetry C 18 (3×10 cm, 5 µm) columns. Analytical RP-HPLC was performed using a XBridge OST C18 2.5 µm column. Compounds were detected by UV absorption at 260 nm. Mass spectra were recorded on a MALDI Voyager DE RP time-of-flight (TOF) spectrometer (Applied Biosystems, Framingham). Two different matrix were used: 2,4,6-trihydroxiacetophenone (THAP: 10 mg/mL in ACN:H 2 O 1:1 v/v, 0.1% TFA); ammonium citrate (CA: 50 mg/mL in H 2 O) and sinapinic acid (SA: 10 mg/mL in ACN:H 2 O 1:1 v/v, 0.1% TFA). HPLC conditions: conditions for semi-preparative HPLC: HPLC solutions were solvent A: 5% acetonitrile (ACN) in 100 mM triethylammonium acetate (TEAA), pH 6.5 and solvent B: 70 % ACN in 100 mM triethylammonium acetate (pH 6.5). Column: PRP-1 (Hamilton) 250 × 10 mm. Flow rate 3 mL/min linear gradient from 15 to 100% in B (DMT on) and 0 to 50% in B (DMT off) were used with UV detection at 260 nm. Conditions for analytical HPLC: HPLC solutions were solvent A: 5% ACN in 100 mM TEAA, pH 6.5 and solvent B: 70% ACN in 100 mM triethylammonium acetate (pH 6.5). Column: XBridge OST C18 2.5 µm. Flow rate 1 mL/min linear gradient from 0 to 50% in B (DMT off) were used with UV detection at 260 nm. Then, the N-Boc group from resins 4 and 7 were deprotected with a mixture of TFA:DCM (2:3, v/v; 1 × 1 min; 1 × 30 min) and subsequently washed with DCM (4 × 30 s); DIPEA:DCM (1:19, v/v; 3×1 min) and DCM (4×30 s). The resins were split into two parts and trityl derivatives 10-12 were introduced in using the same method as the respective amino acids (PyBOP, HOBt, DIPEA in DMF at room temperature). After an acetylation reaction, we obtained the desired Trityl-O-SAP 5 and 8. The functionalization of the resulting trityl-peptide solid supports was determined by measuring the absorbance of the trityl cation released from the solid support upon acid treatment.
Then, trityl-peptide solid supports 5 and 8 were transferred directly to a DNA synthesizer (DMT on). After assembling the corresponding sequences (Dickerson-Drew dodecamer and phosphorothioate oligonucleotide), the resulting solid supports were treated with ammonia solution (32%) and the corresponding modified oligonucleotides were desalted (Sephadex, NAP-10) and purified by semipreparative reverse phase HPLC. DMT group was removed by a 30 min treatment with 80% acetic acid and removal of the acetic acid by extraction with ether. Finally, the desired oligonucleotide-peptide conjugates 6 and 9 were obtained after desalting (Sephadex, NAP-10). SAP-antisense phosphorothioate conjugates 6c and 9c were obtained by DNA precipitation protocols (see below) instead of using Sephadex.
DNA precipitation protocols DNA conjugates were transferred to a container where it fills one fourth the total volume (a 500 µL tube should have no more than 125 µL of DNA). We added one-tenth volume of sodium acetate buffer to equalize ion concentrations. Then, two volumes of cold 100% ethanol were added. Mixtures were cooled at −20 • C for at least 1 h. Finally, we centrifugated the samples for 15 min at 4 • C in a microcentrifuge and remove supernatants. We evaporated the remaining ethanol in a 37 • C water bath.
Introduction of the guanidinium groups SAP-oligonucleotide conjugates 6 and 9 (∼1.5 OD) were treated with a solution (125 µL) and were prepared as follows: O-methylisourea chloride (100 mg) in water (100 µL) and ammonia (32%; 125 µL). Reaction mixtures were heated at 55 • C overnight. The solvent was then removed and the respective conjugates were desalted (Sephadex, NAP-5). SAP-oligonucleotide conjugates 13 and 14 were obtained and were checked using analytical HPLC.
Thermal denaturation experiments
Optical measurements were carried out on a Jasco V-650 spectrophotometer. Prior to the experiments, the SAP-oligonucleotide conjugates (each at a final concentration of ∼2.2 to 3.7 µM), were mixed in 50 mM NaCl, 10 mM sodium phosphate buffer, pH 7.0 conditions. A heating-cooling-heating cycle in the 20 to 90 • C temperature range was applied. T m values were determined from the maxima of the first derivative plots of absorbance versus temperature.
Cell culture SH-SY5Y cells were cultured at 37 • C, 5% CO 2 in Dulbecco's Modified Eagle's Medium (DMEM; GIBCO) supplemented with 10% fetal bovine serum. Cells were regularly passaged to maintain exponential growth. Twenty-four hours before transfection at 50-80% confluency, cells were trypsinized and diluted 1:5 with fresh medium (1-3 × 10 5 cells/mL) and transferred to 24-well plates (500 µL per well). Two luciferase plasmids, Firefly luciferase (pGL3) and Renilla luciferase (pRL-TK) (Promega), were used as reporter and as control, respectively.
Transfection of SAP-oligonucleotide phosphorothioate conjugates using Lipofectamine 2000
Renilla and Firefly luciferase vectors (0.1 and 1.0 µg per well, respectively), unmodified and modified SAP-oligonucleotide phosphorothioate conjugates (6c, 6d, 9c, 9d, 13c, and 14c, respectively; 60 nM per well), and a scrambled oligonucleotide (Scr; 60 nM per well) was transfected into the cells using Lipofectamine 2000 (Invitrogen) at 6.5 µg/ mL as described by the manufacturer for adherent cell lines. The final volume was 600 µL per well. The cells were harvested 24 h after transfection and lysed using a passive lysis buffer (100 µL per well) according to the instructions from the Dual-Luciferase Reporter Assay System (Promega). The luciferase activities of the samples were measured using a MicroLumaPlus LB 96V Luminometer (Berthold Technologies) with a 2 s delay time and an integrate time of 10 s. The following volumes were used: 20 µL of sample and 30 µL of each reagent (Luciferase Assay Reagent II and Stop & Glo Reagent). The inhibitory effects generated by SAP-oligonucleotide phosphorothioate conjugates were expressed as normalized ratios between the reporter GL3 (firefly) luciferase gene and the control RL (Renilla) luciferase gene.
Transfection of SAP-oligonucleotide phosphorothioate conjugates in the absence of Lipofectamine 2000
Renilla and Firefly luciferase vectors (0.1 and 1.0 µg per well, respectively) were transfected into the cells using Lipofectamine 2000. Cells were incubated with the plasmids for 5 h. The medium was discarded and the cells were washed with PBS. Then, 500 µL of fresh medium was added to each well. Finally, 100 µL of SAP-oligonucleotide phosphorothioate solutions (164.4, 14.1, 57.3, 15.4, 23.6, and 64.8 µM for 6c, 6d, 9c, 9d, 13c, and 14c, respectively, in PBS) was added to each well (300 nM per well). Thirty-six hours after transfection, cell lysates were prepared and analyzed using the Dual-Luciferase Reporter Assay System as described above.
Transfection of SAP-oligonucleotide phosphorothioate conjugates using SAP as a transfection agent Renilla and Firefly luciferase vectors (0.1 and 1.0 µg per well, respectively) were transfected and cells were incubated following the same procedure as described before. The medium was discarded and the cells were washed with PBS. Then, 500 µL of fresh medium was added to each well. Then, 100 µL of SAP-oligonucleotide phosphorothioate conjugates with SAP forming polyplexes in PBS were added to each well (150 and 300 nM per well) which were previously incubated at 37 • C for 45 min. Thirty-six hours after transfection, cell lysates were prepared and analyzed using the Dual-Luciferase Reporter Assay System as described above.
Transfection of unmodified oligonucleotide phosphorothioate and SAP
Renilla and Firefly luciferase vectors (0.1 and 1.0 µg per well, respectively) were transfected and cells were incubated following the same procedure as described before. The medium was discarded and the cells were washed with PBS. Then, 500 µL of fresh medium was added to each well. Then, 100 µL of polyplexes in PBS at different concentrations of SAP (20, 30, 40 , and 50 µM) were added to each well (150 and 300 nM per well).
Gel shift assay
Unmodified oligonucleotide phosphorothioate sequence, wt (0.5 µg) was mixed with increasing concentrations of SAP, giving rise to SAP: oligonucleotide molar ratios ranging from 1.2 to 10. Complexes were analyzed by electrophoresis on a 20% polyacrylamide gel at 150 V for 5 h in TBE buffer. Picture were taken in Fujifilm LAS-1000 Intelligent Dark box II using IR LAS-1000 Lite v1.2
Results and discussion
Synthesis of SAP-oligonucleotide conjugates
The conjugation of CPPs to various ODNs can be performed by two different strategies: (1) the non-covalent strategy in which peptides are able to condense with DNA or RNA molecules involving formation of complexes [25] and (2) the covalent strategy that involves the formation of a covalent conjugate between the cargo and the carrier peptide. This strategy can offer several advantages for in vivo applications such as the advantage of being well-defined molecular entities, obtaining better control of the stoichiometry of the CPP-cargo and possible improvement in the stability of the conjugate.
The strategy followed for the synthesis of SAP-oligonucleotide conjugates is outlined on Fig. 1 . It is well known that there is a relationship between the Lys ε-amine group and Orn δ-amine group with their respective HArg and Arg amino acids. Taking into account the SAP structure (ValXLeuProProPro) 3 , the stepwise approach was used in order to synthesize the SAP-oligonucleotides conjugates (1) in their amine form (where X = Lys and Orn, respectively) ( Fig. 1, Step A) . To this end, Boc-amino acids were used and the side chains of Lys and Orn were protected with the base labile Tfa and Fmoc groups, respectively. The first amino acid was linked to the solid support by using the 6-amin- ohexylsuccinyl linker [21] . All together allow the removal of the side chain protecting groups and the liberation of the peptide from the solid support with an ammonia treatment used in oligonucleotide synthesis. However, introducing the three guanidinium groups (Fig. 1, Step B) is not straightforward. It has been described the use of the di-Fmoc-derivative of Arg in a stepwise protocol [31] but this derivative is not commercially available. Post-synthetic approaches have been also described [32, 33] . Recently, our research group reported the synthesis of phosphorothioate conjugates containing different residues of HArg through post-synthetic approach according to the literature [24] . Following this strategy, we were able to introduce the corresponding guanidinium groups (where X = HArg and Arg, respectively) yielding the respective SAP-oligonucleotide conjugates (2) (Fig. 1, Step B) .
In order to demonstrate our proposed strategy and the stability of the SAP-oligonucleotide conjugates, the selfcomplementary Dickerson-Drew dodecamer [34] sequence (5 -CGCGAATTCGCG-3 ; Sequence A) was used as a model sequence. The synthesis of the conjugate 1 began with commercially available PEG-PS (3) (Perseptive Biosystems, 0.19 mmol/g) as starting material. The first spacer was introduced into the resin and then was split equally into two parts: a Lys residue was introduced (Route A), whereas Orn was introduced (Route B) thereby obtaining the appropriate peptides 4 and 7 by standard "Boc and Fmoc chemistry" solid-phase protocols whose peptide sequences were (ValLysLeuProProPro) 3 and (ValOrnLeuProProPro) 3 , respectively. The last Boc group was then removed and the resulting free amines were reacted with three spacer-trityl derivatives (10, 11, and 12), which were obtained in accordance with the literature [35] . Trityl modified solid supports 5 and 8 were transferred directly to a DNA synthesizer and the self-complementary sequence 5 -CGCGAATTCGCG-3 (Dickerson-Drew dodecamer) was assembled. The solid supports were then cleaved with an ammonia solution (32%) at 55 • C overnight and the corresponding SAP-oligonucleotide conjugates were obtained in their amine form. The conjugates were purified according to DMT on based protocols (Fig. 2) and the resulting SAP-oligonucleotide conjugates (6a, 6b, 9a and 9b) were fully characterized by MALDI-TOF mass spectrometry (Table 1S in Supplementary material).
The modification of the amine group to the guanidinium moiety in the peptide sequence was carried out using a postsynthetic modification approach using a freshly prepared solution of O-methylisourea, yielding the expected SAPguanidino conjugates 13a, 13b, 14a, and 14b, respectively (Fig. 3) . The guanidinylation reaction was quantitative yielding the respective conjugates in pure form and without further purification. The resulting conjugates were confirmed using analytical HPLC chromatography and MALDI-TOF mass spectrometry (Table 1S in Supplementary material).
Synthesis of SAP-oligonucleotide phosphorothioate conjugates and biological evaluation
Next, according to the strategy described before, SAP-oligonucleotide conjugates (6c, 6d, 9c, 9d, 13c, 14c) were synthesized and evaluated in gene silencing experiments. We recently described an oligonucleotide phosphorothioate sequence that is active in inhibiting Renilla luciferase gene (5 -AGGTCTTGTTTCCTTTGC-3 ; Sequence B) when is linked to polylysine and polyhomoarginine peptides at 3 -termini [21] . Thus, a series of SAP ((ValXLeuProProPro) 3 with X = Lys, Orn, HArg, and Arg) were covalently combined with the aforementioned Renilla phosphorothioate sequence which was designed and evaluated as potential antisense oligonucleotides for inhibiting the Renilla luciferase gene. SAP-phosphorothioate conjugates (6c, 6d, 9c, 9d, 13c, and 14c, respectively) were obtained from the previous solid supports 5b and 8b following the stepwise solid-phase and post-synthetic modification methods described for the Dickerson-Drew dodecamer. All conjugates were fully characterized by MALDI-TOF mass spectrometry (see Table 1S in Supplementary material), except for 9d in which we were not able to detect the expected mass by spectrometry. In order to determine whether we had conjugate 9d in our hands, all conjugates were analyzed by denaturing polyacrylamide gel electrophoresis (PAGE) in 20% polyacrylamide, 8 M urea (see Fig. 2S in Supplementary material). As expected, the conjugate 9d showed similar retention than the rest of the SAP-antisense phosphorothioate conjugates. The inhibitory properties of the resulting SAP-antisense phosphorothioate conjugates were analyzed in SH-SY5Y cells. The cells were co-transfected with two luciferase plasmids (Renilla and firefly; target and internal controls, respectively), SAP-antisense phosphorothioate conjugates (6c, 6d, 9c, 9d, 13c , and 14c at 60 nM), a scrambled sequence (Scr) and the same scramble sequence conjugated with SAP containing Orn using commercial Lipofectamine 2000. We also included the antisense phosphorothioate sequence without SAP (wt). The luciferase activities were , 6c, 6d, 9c, 9d, 13c, 14c , Scr, and Scr-Orn) (60 nM per well) targeting the Renilla luciferase mRNA expressed in SH-SY5Y cells. Transfection of antisense oligonucleotides was carried out by using Lipofectamine 2000. Two scrambled sequences (Scr and ScrOrn) gave no Renilla luciferase inhibition measured by using a luminometer 22 h after transfection. The results, showing Renilla luciferase activity normalized to firefly luciferase, are shown on Fig. 4 . Interestingly, all SAP-oligonucleotide conjugates demonstrated gene knockdown activities (71, 62, 81, 82, 77, and 81% for 6c, 6d, 9c, 9d, 13c, and 14c, respectively) similar to the phosphorothioate sequence with no peptide (82% for wt). These results confirm that the SAP as a modification does not disrupt antisense activity nor does it interfere with cellular activity. Next, we carried out transfection experiments in the absence of lipofectamine in order to know the capacity of our conjugates to impart cellular uptake. After incubating the two luciferase plasmids for 5 h, the cell medium was discarded and the cells were incubated again with a fresh medium; the SAP-antisense phosphorothioate conjugates (6c, 6d, 9c, 9d,  13c, and 14c) and the phosphorothioate sequence without peptide (wt) at 300 nM. The luciferase activities were measured 36 h after transfection. Unfortunately, the conjugates were not able virtually to penetrate SH-SY5Y cells by themselves (3, 3, 3, 2, 1, and 0% knockdown of Renilla expression at 300 nM for 6c, 6d, 9c, 9d, 13c, and 14c, respectively) ( Fig. 3S in Supplementary material ).
Transfection efficiencies with unmodified ASO phosphorothioate and SAP forming complexes
The ability of certain cationic peptides to condense DNA, specifically Arg-rich peptides for improving DNA delivery has been described [36] . The formation of non-covalent complexes between CPPs and oligonucleotides has been reported by several research groups and the complex formation has been also characterized using different biophysical Fig. 5 Gene-specific silencing activities for unmodified phosphorothioate oligonucleotide (wt) with and without SAP (300 nM per well) targeting the Renilla luciferase mRNA expressed in SH-SY5Y cells. The molar ratios tested for gene knockdown were 4:1, 6:1, 8:1, and 10:1, respectively (peptide:antisense oligonucleotide). Transfection of antisense oligonucleotide was carried out by using SAP. Scrambled sequence (Scr) gave no Renilla luciferase inhibition. The bar named wt is the result of luciferase activity without using SAP as transfecting agent techniques [37] . Recently, the ability of SAP to translocate human cell membranes has been reported. This property is in agreement with the inherent properties to the amphipathic helix character of the SAP when Arg is present in the peptide sequence thereby being most efficient for cellular uptake process [15, 30] . Furthermore, due to its non-viral origin, amphipathic character and solubility in water, SAP could a priori present several advantages as a transfection agent taking advantage of its positive charges.
First, we evaluated the amount of required SAP ((ValArg LeuProProPro) 3 ) in which the unmodified antisense phosphorothioate is able to form complexes. We performed a gel shift assay to evaluate the amount of SAP that efficiently interacted with an unmodified phosphorothioate oligonucleotide, wt (Fig. 1S in Supplementary material) . Several concentrations of the peptide were added, from 1.2-fold molar excess of the peptide compared with wt oligonucleotide to a tenfold molar excess. We observed that SAP was able to retard completely the oligonucleotide phosphorothioate, wt at a molar ratio of 10:1, as shown in Supplementary  Fig. 1S , lane 7.
To assess whether the interaction of the SAP with the oligonucleotide phosphorothioate, as shown in the gel shift assay, was able to impart cellular uptake in the absence of a transfection agent, we performed the experiments described before in SH-SY5Y cells using pGL3 as a reporter gene. The molar ratios tested for gene knockdown were 4:1, 6:1, 8:1, and 10:1, respectively (peptide:antisense oligonucleotide). Interestingly, we observed that the majority of the complexes had gene-specific inhibitory properties at 300 nM thereby obtaining promising results (around 40% of inhibition efficacy in all cases), except for the first case (fourfold molar excess of SAP) which its activity was detrimental (Fig. 5) . This is not surprising according to the SDS-PAGE where we clearly observed the complex formation using at least sixfold of peptide. A scramble sequence (Scr) was also used in this study as a control to establish that the gene knockdown was specific. This sequence was only complexed with the peptide at a 6:1 M ratio yielding no effect on luciferase expression. Experiments at 150 nM were also performed. As expected, we clearly observed that SAP and unmodified phosphorothioate (wt) complexes significantly decreased the luciferase activity in a concentration-dependent manner (see Fig. 4S in Supplementary material).
Transfection efficiencies with SAP-oligonucleotide phosphorothioate conjugates and SAP forming complexes Next, we studied the use of the SAP as transfecting agent for the SAP-antisense conjugates. To this end, we analyzed the gene knockdown effect in SH-SY5Y cells by using SAPantisense conjugates (6c, 6d, 9c, 9d, 13c , and 14c, respectively) along with SAP acting as a transfecting agent in a sixfold molar excess (peptide: SAP-antisense conjugate). We subjected the same protocol as described before for unmodified antisense oligonucleotide to perform in vitro transfections at 150 nM. Notably, we observed an improvement in the activities inhibition when SAP was used as a transfection agent. The majority of SAP-antisense conjugates in combination with SAP were able to inhibit Renilla gene expression thereby slightly improving the activities compared to the experiments previously described without using any transfection agent (11, 20, 26, 27, 14 , and 26% for 6c, 6d, 9c, 9d, 13c, and 14c, respectively) ( Fig. 5S -A in Supplementary material). Although the majority of the conjugates showed similar activities to those obtained with unmodified antisense:SAP polyplexes, surprisingly, we found that conjugates containing Orn and Arg in their peptide sequence (9c, 9d, and 14c) had slightly better transfection efficiencies than conjugates containing Lys and HArg (6c, 6d, and 13c).
We also evaluated the inhibitory properties of SAP-antisense phosphorothioate conjugates using SAP as a transfection agent at 300 nM and 6:1 molar (peptide: SAP-antisense conjugate) ratio. Surprisingly, only SAP-antisense conjugates containing Orn (22 and 18% for 9c and 9d, respectively) were able to knockdown gene expression (Fig. 5S-B in Supplementary material), whereas the activities in gene knockdown expression for SAP-antisense conjugates containing Lys, HArg, and Arg (6c, 6d, 13c, and 14c, respectively) were detrimental (see Fig. 5S in Supplementary material). To our surprise, transfections carried out at 300 nM did not keep a typical dose-response behavior compared to the experiments performed at 150 nM as we observed previously with polyplexes containing unmodified antisense oligonucleotide (wt). These results might be explained in light of the potential cytotoxic effects imparted by some conjugates in combination with the peptide at high concentrations on the SH-SY5Y cells thereby suggesting that gene knockdown expression might be compromised at 300 nM.
Finally, in view of all these results, we compared the effect of SAP as a transfection agent to lipofectamine in the same gene knockdown experiments and cell line. SAP-antisense oligonucleotide conjugates containing Orn and Arg (9c, 9d, and 14c) were chosen to examine the corresponding transfection efficiencies, discarding the rest of the conjugates. As expected, experiments carried out with lipofectamine gave better results in gene knockdown effects than SAP in our hands at both 60 and 150 nM (Fig. 6) . In this case, we also observed that the gene inhibitory properties of the conjugates when SAP is used as transfecting agent were better at lower oligonucleotide concentration (60 nM) than at higher concentration (150 nM). This effect was not seen when transfection was done with Lipofectamine. These data indicate that the formation of efficient transfecting polyplexes of conjugates with the SAP is dependent of the concentration of both peptide and oligonucleotide conjugate and, for some reason, at higher conjugate concentration, the polyplexes formed may not be efficient for cell transfection. But, at lower concentration of oligonucleotide conjugate, the polyplexes formed are efficient for transfection. Best results were obtained at 60 nM with the Orn containing conjugates (62% inhibition 9c, 67% inhibition 9d). In these conditions, the molar ratio between peptide and oligonucleotide conjugate is 6:1 while in the lipofectamine experiments lipofectamine is used at approximately 100 molar excess and reaches 81-82% inhibition.
Thermal denaturation experiments
The duplex stabilities of conjugates 6, 9, 13, and 14 (phosphate and phosphorothioate conjugates, respectively) were measured using the following conditions: 50 mM NaCl, 10 mM sodium phosphate buffer, pH 7.0 (Table 1) . Under these conditions, all phosphate conjugates (amine and guanidinium series, respectively) showed higher T m values than the unmodified oligonucleotide (T m = 44 • C for the Dickerson-Drew dodecamer). The higher stabilities were found in the Lys ( T m 12.4, 17.8 • C for 6a and 6b, respectively) and Orn ( T m 14.4, 14.8 • C for 9a and 9b, respectively) conjugates. Duplexes carrying HArg ( T m 10.0, 12.2 • C for 13a and 13b, respectively) and Arg ( T m 15.0, 7.0 • C for 14a and 14b, respectively) were, in general, less stable. In the case of phosphorothioate conjugates, the unmodified antisense oligonucleotide melted at 30.5 • C; and most of the conjugates had a slight stabilization ( T m 1.5-3.4 • C) except conjugate 9c that melted at a temperature slightly lower than the unmodified phosphorothioate (T m = 29.9 • C). 
Conclusions
We synthesized two different amphipathic proline-rich peptide (SAP) families covalently linked to oligonucleotides using spacers of different lengths between both biomolecules. In general, both SAP-oligonucleotides and SAP-antisense phosphorothioate conjugates containing Lys in their structure were obtained with a higher yield than the SAPoligonucleotide conjugates containing Orn. This difference in reactivity could be attributed to the existing side-reactions consisting of the premature and undesired removal of the Fmoc group caused by a primary amine of sufficient basicity like the amine group of Orn present in the peptide resin [38] . The introduction of guanidinium groups was carried out using post-synthetic approximation with better results and purity levels.
Studies in the inhibition of gene expression showed that the introduction of the SAP at 3 -position of an antisense oligonucleotide does not affect antisense activity. However, the cell uptake experiments that we carried out with the conjugates were compromised. This lack of activity could be attributed to a poor cellular uptake of SAP conjugates in absence of lipofectamine. Next, we carried out gene knockdown experiments using SAP itself as a transfection agent due to its advantages as non-viral origin, amphipathic character and the absence of cytotoxic effects at high concentrations. SAP was able to form polyplexes with the corresponding SAP-antisense conjugates, obtaining promising results for SAP-antisense conjugates containing Orn in their peptide sequence. We also evaluated the effect of complexation between SAP and unmodified antisense phosphorothioate sequence thereby also obtaining promising results of around 40% of gene expression inhibition at 300 nM. This first generation of conjugates complexed with amphipathic SAP represent a promising lead for future optimization in both antisense therapy and RNA interference.
Finally, we measured the thermal stability of duplexes carrying SAP and found there was a remarkable stabilization of the duplex induced by the presence of the positively charged peptide.
